加载中
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
前收盘价
US$4.97
−US$0.15 · -2.93%
盘中时间采用ET。市场数据可能有所延迟。
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
日内区间
当前US$4.97
52周区间
当前US$4.97
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
54
多空交织
风险
75
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
日内区间
当前US$4.97
52周区间
当前US$4.97
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 5266 USD | 4268 USD | 240 USD | — | — |
| 毛利 | −5266 USD | −4268 USD | −240 USD | — | — |
| 研究与开发 | 146.67万 USD | 34.22万 USD | 95.46万 USD | 160.89万 USD | 13.72万 USD |
| 销售、一般及管理费用 | 476.56万 USD | 331.66万 USD | 179.7万 USD | 162.6万 USD | 171.87万 USD |
| 营业费用 | 623.75万 USD | 365.88万 USD | 275.16万 USD | 129.4万 USD | 33.43万 USD |
| 利息收入 | 26.34万 USD | 9.58万 USD | 2134 USD | 1554 USD | 2424 USD |
| 利息支出 | 9522 USD | 9270 USD | 5.29万 USD | — | — |
| 折旧和摊销 | 5266 USD | 4268 USD | 240 USD | — | 234.83万 USD |
| 营业利润 | −623.75万 USD | −366.3万 USD | −275.18万 USD | −437.53万 USD | −33.43万 USD |
| 净利润 | −693.64万 USD | 101.18万 USD | −5115.9万 USD | 801.43万 USD | 823.04万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年2月2日 | 1:6 | — | — |
股票拆分 | 2025年5月5日 | 1:8 | — | — |
股票拆分 | 2024年11月26日 | 1:75 | — | — |
已生效 2026年2月2日
1:6
已生效 2025年5月5日
1:8
已生效 2024年11月26日
1:75
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
